Evaluating WM-S1-030 for advanced solid tumors

A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors

This study is testing a new oral medication called WM-S1-030 to see if it is safe and effective for people with advanced solid tumors.

Quick facts

• Phase: PHASE1
• Study type: Interventional
• Enrollment: 100 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Wellmarker Bio (industry)
• Drugs / interventions: rilotumumab, cetuximab, crizotinib, chemotherapy, radiation
• Locations: 6 sites (Clayton, Victoria and 5 other locations)
• Trial ID: NCT04801095 on ClinicalTrials.gov

What this trial studies

This Phase I study investigates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WM-S1-030 in patients with advanced or metastatic solid tumors. The study is divided into two parts: a dose-escalation phase to determine the maximum tolerated dose (MTD) and a dose-expansion phase to further assess the drug's efficacy and safety. Participants will receive oral WM-S1-030 as monotherapy, and the study will also evaluate the effects of dosing intervals and food on drug absorption. The goal is to identify a recommended dose for further clinical evaluation.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with advanced or metastatic solid tumors that have progressed after standard treatments.

Not a fit: Patients with early-stage tumors that are resectable or those who have not yet received standard therapies may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients with advanced solid tumors who have limited or no effective therapies available.

How similar studies have performed: Other studies have shown promise with similar dose-escalation approaches in advanced solid tumors, indicating potential for success.

Eligibility criteria

Inclusion Criteria:

1. Aged ≥18 years.
2. Able and willing to sign the informed consent form (ICF).
3. Have at least 1 evaluable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
4. Have histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor which has progressed after treatment with standard therapies and for which no effective standard therapy is available or patient has refused, has a contraindication, or is intolerant to standard therapies.
5. Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
6. Must have archived frozen tissue available (collected within 3 months before screening) or consent to a pre-treatment biopsy.
7. Must be willing to consent to up to 2 on-treatment biopsies.
8. Have a life expectancy of at least 12 weeks.
9. Have adequate hematological functions and blood coagulation.
10. Have adequate hepatic function at screening.
11. Have adequate renal function at screening.
12. QT interval corrected for heart rate using Fridericia's method ≤470 msec.
13. Agree to abide by contraception requirements.
14. Body mass index between 18 and 35 kg/m2 (exclusive)

Exclusion Criteria:

1. Have received any prior approved or investigational treatment with RON and/or tyrosine-protein kinase Met (hepatocyte growth factor receptor) such as rilotumumab or crizotinib.
2. Have received any cytotoxic chemotherapy, investigational agent (or medical device), anticancer drug, hormone therapy, or radiation therapy for treatment within 4 weeks or therapeutic radiopharmaceuticals taken within 8 weeks prior to the first administration of IP. Point (or limited) radiation to a site of bone pain, with the exception of patients receiving radiation to more than 30% of the bone marrow, will be allowed.
3. Have known hypersensitivity to WM-S1-030 and/or excipient.
4. Have ≥ Grade 2 unresolved toxicity related to prior anticancer therapy excluding alopecia.
5. Have received drugs or herbal supplements within 2 weeks prior to the first administration of IP which are known to be inhibitors or inducers of cytochrome P450 (CYP)3A4 including, but not limited to, cannabinoids, ketoconazole, itraconazole, posaconazole, voriconazole, rifampicin, phenytoin, St. John's Wort, carbamazepine, or hyperforin.
6. Have any primary central nervous system (CNS) tumors or known CNS metastases unless clinically stable (defined as without evidence of progression by imaging at least 4 weeks prior to the first administration of IP; any neurologic symptoms have returned to baseline), no evidence of new or enlarging brain metastases, and not using steroids or seizure medications (unless on stable doses) for at least 7 days prior to the first administration of IP.
7. Have previously undergone drainage of ascites and/or pleural effusion within 4 weeks prior to screening, or have clinically significant effusions at screening.
8. Have any of the following ocular criteria:

   1. Symptomatic retinal vein occlusion or central serous retinopathy defined as fluid accumulation between the retinal pigment epithelium and the outer segment of the eye
   2. Symptomatic neovascular age related macular degeneration (neovascular/wet age related macular degeneration) or non proliferative diabetic retinopathy with macular edema
   3. Uncontrolled glaucoma, defined as intraocular pressure \>21 mmHg despite treatment or history of previous glaucoma filtration surgery
   4. Presence of active intraocular inflammation, uveitis, keratitis, keratoconjunctivitis, keratopathy, corneal abrasion inflammation, or ulceration
   5. Any other clinically significant risk factor for ocular disorders described above
9. Have had major surgery within 4 weeks prior to the first administration of IP. Patients should have recovered from the effects of major surgery or significant traumatic injury within 14 days prior to administration of the IP. Major surgery is defined as requiring more extensive procedure than that including local anesthesia (general anesthesia, respiratory assistance, or regional anesthesia) or open biopsy.
10. Have serious non-healing wounds, ulcers, or bone fractures, except for traumatic fractures not requiring surgical intervention.
11. Have an active infection treated with systemic anti-infectives within 2 weeks prior to the first administration of IP. Prophylactic anti-infectives that are not inhibitors or inducers of CYP3A4 are permitted.
12. Have concurrent unstable or uncontrolled systemic diseases such as the following:

    1. Uncontrolled hypertension despite treatment (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg)
    2. Clinically significant arrhythmia, unstable angina, congestive heart failure (class III or IV of New York Heart Association), or acute myocardial infarction within 6 months prior to screening
    3. Concurrent active systemic infections requiring systemic antibiotics or antifungals (exception for management of cetuximab-related rash)
    4. Active infections of hepatitis B, hepatitis C, or history of human immunodeficiency virus
    5. Any other chronic disease, which, at the discretion of the investigator, could jeopardize the safety of patients or patients' compliance with the protocol.
    6. Clinically significant venous thromboembolism requiring systemic anticoagulant (exception for prophylactic use)
13. Have a history of gastrointestinal or trachea-esophageal fistulas.
14. Gastrointestinal perforation, non-gastrointestinal fistulas, inflammatory bowel disease, or other bowel diseases accompanying chronic diarrhea within 6 months prior to screening.
15. Current (or planned) pregnancy or breastfeeding from screening to at least 6 months following the last IP administration.
16. Any condition, at the discretion of the investigator, which puts the patient at risk to participate in the study.

Where this trial is running

Clayton, Victoria and 5 other locations

• Monash Medical Center — Clayton, Victoria, Australia (RECRUITING)
• Austin Hospital — Heidelberg, Victoria, Australia (RECRUITING)
• Linear Clinical Research Limited — Nedlands, Western Australia, Australia (RECRUITING)
• Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do, Korea, Republic of (RECRUITING)
• Severance Hospital, Yonsei University Health System — Seoul, Korea, Republic of (RECRUITING)
• Samsung Medical Center — Seoul, Korea, Republic of (RECRUITING)

Study contacts

• Study coordinator: Wellmarker Bio

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Cholangiocarcinoma, Head and Neck Cancer